O. Van Cutsem

发表

Prognostic factors for patients with small cell lung carcinoma

V. Ninane, M. Paesmans, J. Sculier, 2000, Cancer.

Second-line paclitaxel in non-small cell lung cancer initially treated with cisplatin: a study by the European Lung Cancer Working Party

J. Lafitte, V. Ninane, M. Paesmans, 2007, British Journal of Cancer.

A phase III randomised study comparing concomitant radiochemotherapy with cisplatin and docetaxel as induction versus consolidation treatment in patients with locally advanced unresectable non-small cell lung cancer.

J. Lafitte, P. van Houtte, M. Paesmans, 2018, Lung cancer.

Evaluation of the TN sub-staging in patients with initially unresectable stage III non-small cell lung cancer treated by induction chemotherapy. The European Lung Cancer Working Party.

J. Lafitte, V. Ninane, P. van Houtte, 1998, Lung cancer.

A three-arm phase III randomised trial assessing, in patients with extensive-disease small-cell lung cancer, accelerated chemotherapy with support of haematological growth factor or oral antibiotics

J. Lafitte, V. Ninane, M. Paesmans, 2001, British Journal of Cancer.

A phase II randomised trial comparing the cisplatin-etoposide combination chemotherapy with or without carboplatin as second-line therapy for small-cell lung cancer.

J. Lafitte, V. Ninane, M. Paesmans, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Long-term survival after chemotherapy containing platinum derivatives in patients with advanced unresectable non-small cell lung cancer. European Lung Cancer Working Party.

M. Paesmans, J. Sculier, J. Thiriaux, 1994, European journal of cancer.

Randomized trial comparing induction chemotherapy versus induction chemotherapy followed by maintenance chemotherapy in small-cell lung cancer. European Lung Cancer Working Party.

M. Paesmans, J. Sculier, J. Klastersky, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Chemotherapy improves low performance status lung cancer patients

J. Lafitte, V. Ninane, M. Paesmans, 2007, European Respiratory Journal.

Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. The European Lung Cancer Working Party.

M Paesmans, J P Sculier, M. Paesmans, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomised phase III trial comparing consolidation treatment with further chemotherapy to chest irradiation in patients with initially unresectable locoregional non-small-cell lung cancer responding to induction chemotherapy. European Lung Cancer Working Party.

J. Lafitte, V. Ninane, P. van Houtte, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Response to chemotherapy has predictive value for further survival of patients with advanced non-small cell lung cancer: 10 years experience of the European Lung Cancer Working Party.

M Paesmans, J P Sculier, M. Paesmans, 1997, European journal of cancer.

A four-drug combination chemotherapy with cisplatin, mitomycin, vindesine and 5 fluorouracile: a regimen associated with major toxicity in patients with advanced non-small cell lung cancer.

M. Paesmans, J. Sculier, F. Ries, 1994, Lung cancer.

Induction chemotherapy with ifosfamide, etoposide, and anthracycline for small cell lung cancer: experience of the European Lung Cancer Working Party.

J. Sculier, J. Thiriaux, G. Bureau, 1995, Seminars in oncology.

A phase III randomised trial comparing sequential to standard chemotherapy in advanced non-small cell lung cancer (NSCLC).

J. Lafitte, M. Paesmans, T. Berghmans, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic factors for response to chemotherapy containing platinum derivatives in patients with unresectable non-small cell lung cancer. (NSCLC).

M. Paesmans, J. Sculier, J. Klastersky, 1996, Lung cancer.

Validation and comparison of several published prognostic systems for patients with small cell lung cancer

J. Lafitte, P. van Houtte, M. Paesmans, 2011, European Respiratory Journal.

Multiple-drug weekly chemotherapy versus standard combination regimen in small-cell lung cancer: a phase III randomized study conducted by the European Lung Cancer Working Party.

M. Paesmans, J. Sculier, F. Ries, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase III randomised trial comparing sequential chemotherapy using cisplatin-based regimen and paclitaxel to cisplatin-based chemotherapy alone in advanced non-small-cell lung cancer.

J. Lafitte, V. Ninane, M. Paesmans, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase II study testing paclitaxel as second-line single agent treatment for patients with advanced non-small cell lung cancer failing after a first-line chemotherapy.

J. Lafitte, V. Ninane, M. Paesmans, 2002, Lung cancer.